within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02C_AntiadrenergicAgentsPeripherallyActing.C02CC03_Guanoxan;

model Guanoxan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 1e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Guanoxan</td></tr><tr><td>ATC code:</td><td>C02CC03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>60</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Guanoxan is a sympatholytic antihypertensive agent, formerly used for the management of high blood pressure. It acts primarily as a neuronal blocker, reducing sympathetic nervous activity. Due to safety concerns, including risks of hepatotoxicity, it is no longer widely used or marketed in most countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data is available for guanoxan. All reported parameters are rough estimates based on its class properties and analogous drugs in the same ATC therapeutic group.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02CC03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Guanoxan;
